Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protara Therapeutics Inc. TARA

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Recent & Breaking News (NDAQ:TARA)

Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

GlobeNewswire August 5, 2021

Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

GlobeNewswire July 7, 2021

Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors

GlobeNewswire June 10, 2021

Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire May 13, 2021

Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview

GlobeNewswire May 6, 2021

Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations

GlobeNewswire April 23, 2021

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 19, 2021

Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

GlobeNewswire April 19, 2021

Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview

GlobeNewswire March 11, 2021

Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference

GlobeNewswire March 10, 2021

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences

GlobeNewswire February 4, 2021

Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors

GlobeNewswire February 2, 2021

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2021

Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer

GlobeNewswire December 7, 2020

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 3, 2020

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences

GlobeNewswire November 24, 2020

Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview

GlobeNewswire November 12, 2020

Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

GlobeNewswire November 11, 2020

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2020

Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

GlobeNewswire September 22, 2020